Compare LASR & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LASR | GLPG |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2018 | 2005 |
| Metric | LASR | GLPG |
|---|---|---|
| Price | $48.01 | $34.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 4 |
| Target Price | ★ $36.29 | $31.33 |
| AVG Volume (30 Days) | ★ 683.4K | 122.2K |
| Earning Date | 02-26-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $227,526,000.00 | ★ $336,643,201.00 |
| Revenue This Year | $31.18 | $1.76 |
| Revenue Next Year | $11.31 | $0.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.05 | 10.31 |
| 52 Week Low | $6.20 | $22.36 |
| 52 Week High | $47.50 | $37.78 |
| Indicator | LASR | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 80.69 | 67.07 |
| Support Level | $42.94 | $32.13 |
| Resistance Level | $47.50 | $34.48 |
| Average True Range (ATR) | 2.59 | 0.82 |
| MACD | 0.62 | 0.06 |
| Stochastic Oscillator | 96.60 | 92.61 |
nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products, which includes semiconductor lasers, fiber lasers, and directed energy products; and Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.